Drug – bio-affecting and body treating compositions – Conjugate or complex of monoclonal or polyclonal antibody,...
Patent
1974-12-06
1976-04-13
Waddell, Frederick E.
Drug, bio-affecting and body treating compositions
Conjugate or complex of monoclonal or polyclonal antibody,...
A61K 3726
Patent
active
039505170
ABSTRACT:
A physiologically acceptable insulin derivative has the terminal amino group of the B chain (B.sub.1, phenylalanine) protected by an acyl group or other blocking group containing up to 7 carbon atoms and the amino group of the A chain (A.sub.1, glycine) is either free or protected by means of an acyl or other blocking group containing no more than four carbon atoms and preferably no more than three atoms other than hydrogen. Pharmaceutical preparations may be prepared containing an effective amount of such an insulin derivative together with a physiologically acceptable diluent. An insulin derivative of reduced antigenicity is obtainable from porcine or bovine insulin by reacting the insulin with an acylating agent or other blocking reagent to acylate or otherwise block the amino group of the B.sub.1 amino acid and optionally block the A.sub.1 and/or B.sub.29 amino acid, followed by purification of the derivative by various methods.
REFERENCES:
patent: 3823125 (1974-07-01), Grant et al.
Lindsay David Gordon
Shall Sydney
National Research Development Corporation
Waddell Frederick E.
LandOfFree
Insulin derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Insulin derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Insulin derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-752969